source
- FDA grants three-month extension for Capricor’s Duchenne therapy deramiocel, sets new action date Nov 22The U.S. Food and Drug Administration has given Capricor Therapeutics a three‑month extension to review additional data for its Duchenne muscular dystrophy cell therapy, deramiocel. The agency has…
- Pharma marketers urged to adopt share-of-answer strategy as AI use surges among physiciansPharma marketers are planning for 2027 as artificial intelligence reshapes how clinicians seek clinical answers. The rise of AI tools means that traditional metrics like share of voice and broad om…